Thus, we combined recently developed mesyl and busyl phosphoramidate ASO modifications with PSMA ligand conjugation, and uncovered an efficient alternative to the classical all-phosphorothioate gapmer ASOs with improved targeted delivery to prostate cancer cells. Here, FOLH1 is linked to prostate cancer.